What is the confirmed market size and growth trajectory for the global pharmaceutical logistics market?
The market was valued at USD 351.2 billion in 2025 and is projected to grow at a CAGR of 7.0% to USD 645.67 billion by 2035. Cold chain logistics is the largest logistics type by revenue. Air freight is the dominant transportation mode by value. Biologics and biosimilars are the fastest-growing product type. Refrigerated 2°C-8°C is the largest temperature range. North America leads by revenue; Asia-Pacific is the fastest-growing region.

What is driving cell and gene therapy logistics as the highest-margin pharmaceutical logistics application?
Cell and gene therapy logistics requires cryogenic storage at -70°C to -196°C liquid nitrogen temperatures, chain-of-custody documentation at single-patient lot level, and delivery against clinical administration schedule windows — creating logistics service requirements where per-shipment value can reach USD 50,000 to USD 500,000 and where logistics failure can result in patient harm from missed treatment windows or product destruction. This combination of extreme temperature requirement, single-patient traceability, and clinical schedule dependency makes cell and gene therapy logistics the most technically demanding and highest-margin pharmaceutical logistics segment.

How does GDP compliance create the regulatory entry barrier that sustains premium pharmaceutical logistics pricing?
Good Distribution Practice compliance — enforced by FDA, EMA, WHO, and national medicines regulators — requires pharmaceutical logistics providers to implement and document temperature-controlled storage, qualified cold chain equipment, temperature mapping validation, deviation management procedures, and regular regulatory authority inspection readiness. The investment required to achieve and maintain GDP qualification creates a regulatory certification barrier that non-specialist logistics providers cannot meet without multi-million-dollar infrastructure and procedure implementation — sustaining premium pharmaceutical logistics pricing above general freight rates.

How does serialisation and track-and-trace regulation create structured pharmaceutical logistics technology investment demand?
The U.S. Drug Supply Chain Security Act (DSCSA) requirement for end-to-end pharmaceutical product serialisation and electronic tracing, EU Falsified Medicines Directive serialisation mandates, and equivalent national regulations across Japan, South Korea, Saudi Arabia, and Brazil require pharmaceutical logistics providers to implement serialisation scanning, electronic product information exchange, and verification systems at every logistics handling point — creating mandatory technology investment demand from pharmaceutical companies and their logistics partners.

What is driving clinical trial material logistics as the fastest-growing pharmaceutical logistics sub-segment?
Clinical trial material logistics — distributing investigational medicinal products from central pharmacy to clinical trial sites across multiple countries, with patient kit manufacturing, randomisation management, and temperature-controlled delivery at study-specific schedules — is growing fastest because the global clinical trial outsourcing market is expanding as pharmaceutical companies increasingly use CRO and CDMO partners who require specialist IMP logistics support across international trial geographies.

How does ultra-low temperature logistics below -70°C require fundamentally different infrastructure from standard pharmaceutical cold chain?
Ultra-low temperature logistics at -70°C requires dry ice or cryogenic liquid nitrogen as the cooling medium rather than mechanical refrigeration — with dry ice sublimation rates creating a finite shipment duration window of 24 to 96 hours depending on container insulation. Cryogenic -196°C liquid nitrogen logistics additionally requires specialist dry shippers that maintain temperature through dewar vessel vacuum insulation rather than active cooling, creating entirely different equipment, safety, and handling requirements from conventional 2°C-8°C pharmaceutical cold chain.